Ayala Pharmaceuticals Inc (ADXS)

[$5.95akadawson-m]

Have you read that CAR-T has already data and at $400k per treatment per individual, you can see that ADXS has more going for it. Nonetheless there are many on this board that, for some unknown reason, want to trash the company. Not even Merck has come up with a substantial OR.

All small biotech start off with a small cohort because they are funding the whole package. That's the way it is until they show significant or relative % of patients living longer, which they have. In fact, to date, not many have shown this kind of data. But the shorts have an iron grip on this stock. The shorts have more money than potential longs or even the BOD.

We just have to wait it out at our own peril.